ClinicalTrials.gg
RecruitingNCT06677970Updated Feb 13, 2026

Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)

A Phase 3 interventional study of BP lowering drugs (nicardipine, labetalol, urapidil) and BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil) in Acute Ischemic Stroke, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Yonsei University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Ischemic Stroke by Yonsei University — 4 open to participants now, 5 under way, 2 of them phase 3. Ischemic Stroke · Yonsei University.

Started
2024
the only one that year
Phase 3
3 of 11
2 open now
Registered
9th of 11
by date

Among the 11 studies in Ischemic Stroke by Yonsei University, this one is the only one that started in 2024, is one of 3 in phase 3, and was the 9th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 11 studies in Ischemic Stroke by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ischemic Stroke by Yonsei University, or all of them as a file.
02

Study summary

Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.

Four randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was associated with worse functional outcomes at 3 months. Specifically, lowering BP too aggressively after successful reperfusion could worsen outcomes by reducing perfusion to the ischemic penumbra. Therefore, this study will investigate whether a more targeted blood pressure elevation strategy could improve patient prognosis compared to standard BP control in patients with sustained systolic blood pressure (SBP) \<150 mmHg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion.

This is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design, aimed at comparing intensive and standard BP control strategies in acute ischemic stroke patients. Participants will be randomized 1:1 into either an intensive BP control group (targeting a 20% systolic BP increase, capped at less than 160 mmHg) or a standard BP control group (systolic BP at or below 180 mmHg).

Read the detailed description
  1. This is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design.
  2. Participants will be randomly assigned in a 1:1 ratio to either an intensive BP control group (targeting a 20% increase from baseline systolic BP, capped at less than 160 mmHg) or a standard BP control group (maintaining systolic BP at or below 180 mmHg).
  3. Randomization: Allocation will be stratified by stroke severity (NIHSS \<15 or ≥15) and participating study center. Randomization will be conducted via a web-based system using a pre-generated randomization table created by a statistician. Investigators will enter stratification variables (study center, NIHSS score) into the system to receive the randomized allocation.
  4. This is a multi-center prospective study involving patients admitted to participating hospitals for acute ischemic stroke between October 2024 and December 2029 (last visit date). The study will include patients who undergo successful intra-arterial reperfusion therapy based on current stroke guidelines.
  5. Data collection will include the medical history, imaging findings, BP parameters (systolic BP, diastolic BP, BP variability), neurological scores, functional recovery, and quality of life (QoL) measures for eligible participants.
  6. Neurological scores, functional recovery, and QoL assessments will be conducted by independent evaluators who are blinded to treatment allocation.
  7. All data will be collected using electronic case report forms (e-CRF), and anonymized imaging data will be sent to the coordinating center.
  8. The coordinating center will perform blinded quantification of imaging results.
03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Blood pressure
  • Ischemic stroke
  • thrombectomy
  • outcome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

\<Inclusion Criteria>

  1. Age ≥20 years
  2. Acute ischemic stroke patients who underwent intraarterial thrombectomy for large vessel occlusion. (ICA, M1, M2, A1, P1, VA and BA)
  3. Patients with successful recanalization after intraarterial thrombectomy (TICI 2b or TICI 3)
  4. Patients with sustained systolic blood pressure (SBP) \<150 mm Hg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion.
  5. Patients with mean SBP \<150 mmHg within 2 hours after successful recanalization (two measurements ≥2 minutes apart).

\<Exclusion Criteria>

  1. Age \<20
  2. Patients who failed recanalization of the intracranial artery after endovascular thrombectomy (modified TICI ≤ 2a).
  3. Patients with systolic blood pressure ≥ 150 mmHg after successful recanalization.
  4. Patients unable to receive antihypertensive medication post-thrombectomy or in whom the investigator believes aggressive blood pressure control could have adverse effects, such as increased risk of hemorrhage.
  5. Patients who developed symptomatic intracranial hemorrhage before study enrollment, after successful recanalization.
  6. Patients with to Phenylephrine.
  7. Patients with contraindications to antihypertensive medications.
  8. Patients with pre-stroke functional disability (modified Rankin Scale, mRS ≥3).
  9. Patients with heart failure and reduced cardiac output, with an (EF) \<40%.
  10. Patients with end-stage renal disease requiring renal replacement therapy, or chronic kidney disease stage 4 with an \<30 mL/min.
  11. Patients currently taking monoamine oxidase (MAO) inhibitors.
  12. Patients with persistent bradycardia with a heart rate \<45 bpm.
  13. Pregnant patients.
  14. Patients with severe medical or surgical comorbidities, including but not limited to: terminal cancer with \<6 months, severe cardiac or aortic disease, severe hematologic disorders, advanced chronic heart failure, severe pneumonia, or sepsis.
  15. Patients who do not consent to participate in the study.
  16. Patients participating in another study that does not allow co-enrollment.
  17. Patients whom the investigator deems unsuitable for study participation for any reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Active comparator
    Conventional BP magnagement group (SBP ≤180 mmHg)

    Drug: BP lowering drugs (nicardipine, labetalol, urapidil)

  • Active comparator
    Intensive BP raising group (20% increase in SBP, maximum of 160 mmHg )

    Drug: BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)

Interventions

  • DrugBP lowering drugs (nicardipine, labetalol, urapidil)

    After successful reperfusion, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.

  • DrugPhenylephrineStudies of PhenylephrinePhenylephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After successful reperfusion, appropriate BP raising (20% increase in SBP, maximum of 160 from baseline SBP) are administered.

06

What researchers measure

Primary outcomes

  1. Functinal independence

    Proportion of patients with a functional independence (defined as mRS ≤ 2) at 3 months, assessed using the modified Rankin Scale (mRS).

    Time frame: 3 months

  2. Symptomatic Intracranial Hemorrhage (sICH)

    Symptomatic Intracranial Hemorrhage (sICH) after Endovascular Treatment Intracranial hemorrhage or hemorrhagic transformation identified on MRI (GRE or SWI) or CT within 24 ± 12 hours or due to clinical worsening. (Symptomatic intracranial hemorrhage is defined according to the European Cooperative Acute Stroke Study III \[ECASS III\] criteria)

    Time frame: 36 hours

  3. Stroke related death

    Stroke related death within 3 months

    Time frame: 3 months

Secondary outcomes

  1. Shift analysis of mRS score distribution.

    Distributional analysis of the modified Rankin Scale (mRS) scores to assess overall functional outcome shift between treatment groups.

    Time frame: 3 months

  2. NIHSS score at 24 hours after endovascular treatment.

    Difference in National Institutes of Health Stroke Scale (NIHSS) scores between at 24 hours post-EVT.

    Time frame: 24 hours

  3. Major Neurological Improvement at 24 hours, defined as either an NIHSS score of 0-1 or an improvement of 8 or more points.

    Proportion of patients achieving substantial neurological recovery within 24 hours after EVT.

    Time frame: 3 months

  4. Sustained vessel recanalization on CTA/MRA at 24 hours

    Evaluation of angiographic reperfusion status (modified Thrombolysis in Cerebral Infarction \[mTICI\] grade ≥2b)

    Time frame: Discharge and 1 month

  5. Proportion of functional independence at 1 month.

    Percentage of patients achieving mRS 0-2 at 1 month.

    Time frame: 3 months

  6. Differences in Euro-Q5 instrument.

    Differences in scores measured by Euro-Q5 scale.

    Time frame: 36 hours to 1 week

  7. Incidence of malignant cerebral edema.

    Frequency of radiologically or clinically confirmed malignant cerebral edema after EVT.

    Time frame: 36 hours

  8. Infarction volumes

    Proportion of functional independence according to infarction volumes in DWI

    Time frame: 36 hours

  9. Using intravenous BP lowering drug

    Proportion of functional independence according to intrvenous BP lowering drug

    Time frame: 3 months

  10. Medication induced BP drop

    Proportion of functional independence according to medication inuced BP drop

    Time frame: 3 months

  11. Collateral circulation measured by Tan scale (good collateral is defined as Tan scale 2-3) in baseline CTA.

    Proportion of functional independence according to the degree of collateral flow

    Time frame: 3 months

  12. Variability in blood pressure (e.g., standard deviation, coefficient of variation, VIM, successive variation, and threshold).

    Evaluation of outcome associations with multiple BP variability indices

    Time frame: 3 months

  13. Outcome comparison by baseline ischemic core burden measured with ASPECTS.

    Proportion of functional independence according to the ASPECTS (Alberta Stroke Program Early CT Score) on CT or MRI.

    Time frame: 3 months

  14. Evaluation of differential outcomes in patients who received IV tPA before EVT.

    Proportion of functional independence according to prior tPA administration.

    Time frame: 3 months

  15. Comparison of outcomes according to presence or severity of intracranial atherosclerotic stenosis.

    Proportion of functional independence according to intracranial arterial stenosis.

    Time frame: 3 months

  16. Assessment of outcome differences by number of thrombectomy passes.

    Proportion of functional independence according to multiple attempts at endovascular recanalization.

    Time frame: 3 months

  17. Evaluation of outcomes relative to attainment and timing of post-EVT BP target.

    Proportion of functional independence according to achieving the target blood pressure and the time to target on outcomes.

    Time frame: 3 months

  18. Outcome comparison by initial angiographic reperfusion grade before BP intervention.

    Proportion of functional independence according to baseline mTICI scores.

    Time frame: 3 months

  19. Assessment of outcome differences between patients with and without early neurological worsening.

    Proportion of functional independence according to neurological deterioration (NIHSS worsening by ≥4 points).

    Time frame: 3 months

  20. Evaluation of outcomes stratified by occlusion site (e.g., ICA, M1, M2).

    Proportion of functional independence according to the occluded vessel involved.

    Time frame: 3 months

  21. Biochemical markers including D-dimer, CRP, or glucose

    Proportion of functional independence according to laboratory findings including D-dimer, CRP, or glucose.

    Time frame: 3 months

  22. Evaluation of vascular stiffness as a determinant of post-EVT outcomes.

    Proportion of functional independence according to estimated pulse wave velocity (ePWV).

    Time frame: 3 months

  23. Small artery disease - white matter hyperintensity

    Proportion of functional independence according to degree of white matter hyperintensity

    Time frame: 3 months

  24. Small artery disease - microbleeds

    Proportion of functional independence according to number of microbleeds

    Time frame: 3 months

  25. Small artery disease - old lacunar infarction

    Proportion of functional independence according to number of old lacunar infarctions

    Time frame: 3 months

  26. Optimal target BP according to AI predicting for functional independence in 10 mmHg increments

    Model-based identification of the optimal SBP target range predicted by AI for favorable outcomes.

    Time frame: 3 months

  27. Occurrence of adverse event or serious adverse event

    Incidence and type of adverse events

    Time frame: 3 months

  28. Treatment failure, defined as failure to achieve target blood pressure on two consecutive measurements within 24 hours after endovascular therapy.

    Rate of unsuccessful BP target attainment during the acute post-procedure period.

    Time frame: 24 hours

  29. Differences in BP variability depending on the antihypertensive agent use (labetalol or nicardipine).

    Comparison of short-term BP stability between BP medication used for post-EVT management.

    Time frame: 24 hours

  30. Differences in causes of death.

    Comparison of mortality causes

    Time frame: 3 months

  31. Diffrences in fuctional outcomes at 1 year.

    Difference in 1-year functional outcomes according to mRS and EQ-5D-5L.

    Time frame: 1 year

  32. Euro-Q5-5L analogue scale.

    Differnec in scores measured by Euro-Q5 scale.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology, Yonsei University College of Medicine
    Seoul, Seoul 120-752, South Korea
    Recruiting
    • Hyo Suk Nam, MD, PhD · Contacthsnam@yuhs.ac · +82 02 2228 1617
08

References and documents

Individual participant data

Plan to share: Yes — After study competition, the participating researcher can submitt the proposal. Publication committee will evaluate the proposal and approve it. After approval, patients data will be shared with researcher.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: The data will be available until the study was published.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2029, 62 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 62 months is above that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Nov 7, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Dec 3, 2029
CompletionEst.
Dec 3, 2029
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677970
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Oct 1, 2024
Primary completion
Dec 3, 2029 (estimated)
Completion
Dec 3, 2029 (estimated)
Last update
Feb 13, 2026

Study contacts

Hyo Suk Nam, MD,PhD
Contact
hsnam@yuhs.ac
82-2-2228-1617

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenylephrine

Start the discussion